Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls.
De Francesco D, Underwood J, Bagkeris E, Boffito M, Post FA, Mallon P, Vera JH, Williams I, Anderson J, Johnson M, Sabin CA, Winston A; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study. De Francesco D, et al. Among authors: mallon p. HIV Med. 2019 Apr;20(4):274-285. doi: 10.1111/hiv.12714. Epub 2019 Feb 8. HIV Med. 2019. PMID: 30734983 Free PMC article.
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group. Bernardino JI, et al. Among authors: mallon pw. Lancet HIV. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30. Lancet HIV. 2015. PMID: 26520926 Clinical Trial.
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.
Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group. Winston A, et al. HIV Med. 2016 Jun;17(6):471-8. doi: 10.1111/hiv.12344. Epub 2015 Nov 26. HIV Med. 2016. PMID: 26611175 Free article.
Patterns of Co-occurring Comorbidities in People Living With HIV.
De Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, Winston A, Reiss P, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study and the AGEhIV Cohort Study. De Francesco D, et al. Among authors: mallon pwg. Open Forum Infect Dis. 2018 Oct 24;5(11):ofy272. doi: 10.1093/ofid/ofy272. eCollection 2018 Nov. Open Forum Infect Dis. 2018. PMID: 30465014 Free PMC article.
Magnetic Resonance Imaging of Cerebral Small Vessel Disease in Men Living with HIV and HIV-Negative Men Aged 50 and Above.
Haddow LJ, Sudre CH, Sokolska M, Gilson RC, Williams IG, Golay X, Ourselin S, Winston A, Sabin CA, Cardoso MJ, Jäger HR; Pharmacokinetics and clinical Observations in PeoPle over fiftY (POPPY) Study Group. Haddow LJ, et al. AIDS Res Hum Retroviruses. 2019 May;35(5):453-460. doi: 10.1089/AID.2018.0249. Epub 2019 Feb 20. AIDS Res Hum Retroviruses. 2019. PMID: 30667282 Free PMC article.
Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment.
Underwood J, De Francesco D, Cole JH, Caan MWA, van Zoest RA, Schmand BA, Sharp DJ, Sabin CA, Reiss P, Winston A; COmorBidity in Relation to AIDS (COBRA) Collaboration and the Pharmacokinetic and clinical Observations in PePle over fiftY (POPPY) Study Group. Underwood J, et al. Open Forum Infect Dis. 2019 May 3;6(6):ofz198. doi: 10.1093/ofid/ofz198. eCollection 2019 Jun. Open Forum Infect Dis. 2019. PMID: 31263729 Free PMC article.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
291 results